UNITY Biotechnology Inc To Discuss The Most Recent UBX1325 Clinical Data Call Transcript
Good morning, and welcome to the Unity Biotechnology conference call and webcast. At this time, all attendees are in a listen-only mode. A question-and-answer session will follow the formal presentations. As a reminder, this call is being recorded and a replay will be made available on the Unity website following the conclusion of the event.
I'd now like to turn the call over to Lynne Sullivan, Chief Financial Officer of Unity Biotechnology. Please go ahead, Lynne.
Thanks, [Tara]. Good morning and thank you for joining Unity Biotechnology's conference call to review the 48-week data from our Phase 2 BEHOLD Study of UBX1325 in patients with DME.
With me on today's call is Anirvan Ghosh, the CEO of Unity Biotechnology; Jamie Dananberg, our Chief Medical Officer; Mike Sapieha, our Chief Scientist; and myself, Lynne Sullivan, the Chief Financial Officer. We are fortunate to have Dr. Robert Bhisitkul, Professor of Ophthalmology and Director of the Retina Fellowship at the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |